Poba / iStock
Oppenheimer, a unit of Oppenheimer Holdings, has hired a new life sciences team to join the firm's healthcare investment banking group.
The team is led by Michael Margolis, who will serve as managing director and co-head of healthcare investment banking along with Marc Cabrera who leads the healthcare services and digital health team.
Most recently, Margolis served as the head of healthcare investment banking at ROTH Capital Partners. He previously held a number of key positions in the financial services and pharmaceutical industries, including roles at Novartis Pharmaceuticals and Eli Lilly. In addition, he is a registered pharmacist from Rutgers University, College of Pharmacy.
Michael is joined by Warren Dunnavant II, managing director of healthcare investment banking. Dunnavant also joins the firm from ROTH Capital Partners, where he previously served as a managing director in healthcare investment banking. Previously, Warren held positions in Investment Banking and Equity Research at Stifel Nicolaus & Co., Legg Mason and Lehman Brothers.
Collectively, Margolis and Dunnavant have executed more than 300 financing and strategic advisory transactions and raised in excess of $12.5 billion during their tenure at ROTH Capital Partners.
"As big pharma continues to deal with patent expirations, we see strong tailwinds for the life sciences sector," said Rob Lowenthal, head of investment banking at Oppenheimer. "In 2015, biotechnologies represented seven of the top 10 drugs and over the next five years, global biotech revenue is estimated to grow to over $300 billion. This fundamental growth trend will drive new company and capital formation across life sciences. With the addition of Michael and his team, Oppenheimer's healthcare investment banking effort is well- positioned for continued success."
Oppenheimer, Appointment, Life science, Healthcare investment banking, Michael Margolis, Warren Dunnavant, US
